Finance

Beta
Lists
ATAI:NASDAQ
AtaiBeckley Inc
$3.95
-12.22%
(-0.55) 1D
$4.00
+1.21% (+0.048)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Open
$4.46
High
$4.48
Low
$3.78
Mkt. cap
1.45B
Avg. vol.
4.78M
Volume
9.24M
52-wk high
$6.72
52-wk low
$2.00
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
Open
$4.46
High
$4.48
Low
$3.78
Mkt. cap
1.45B
Avg. vol.
4.78M
Volume
9.24M
52-wk high
$6.72
52-wk low
$2.00
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
Analyst outlook
Analyst Ratings
Based on 11 analysts giving stock ratings to ATAI in the past 3 months
Strong Buy
Buy
11
Hold
0
Sell
0
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ATAI in the last 3 months.
Highest
Current $3.95
$25.00 (+532.91%)
Average
$14.90 (+277.22%)
Lowest
$10.00 (+153.16%)
News stories
From sources across the web
Profile
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
719.00K
749.00K
1.07M
954.00K
Cost of goods sold
10.51M
14.68M
14.91M
-
Cost of revenue
10.51M
14.68M
14.91M
-
Research and development expenses
582.00K
-
-
17.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.90M
14.50M
24.40M
14.44M
Operating expense
15.48M
14.50M
24.40M
31.86M
Total operating expenses
25.99M
29.18M
39.32M
31.86M
Operating income
-25.27M
-28.44M
-38.25M
-30.90M
Other non operating income
-6.33M
-51.25M
13.99M
1.12M
EBT including unusual items
-27.68M
-61.00M
-544.84M
-29.78M
EBT excluding unusual items
-30.16M
-79.20M
-23.71M
-29.78M
Income tax expense
65.00K
102.00K
3.00K
20.00K
Effective tax rate
-0.23%
-0.17%
-
-0.07%
Other operating expenses
-
-
-
-
Net income
-27.73M
-61.07M
-544.81M
-29.78M
Net profit margin
-3,856.61%
-8,154.07%
-51,108.16%
-3,121.80%
Earnings per share
-0.14
-0.28
-1.73
-0.08
Interest and investment income
248.00K
504.00K
542.00K
-
Interest expense
-264.00K
-
-
-
Net interest expenses
-16.00K
504.00K
542.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.05M
-28.20M
-37.91M
-30.65M
Gain or loss from assets sale
-
-
692.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer